Andrew Dunn
Business Insider
Washington, DC, United States
Contact Andrew
Discover and connect with journalists and influencers around the world, save time on email research, monitor the news, and more.
| Recent: |
|
| Past: |
|
Past articles by Andrew:
How an AI breakthrough from Alphabet's DeepMind 'changed scientific history' and could lead to new cures
Over 1 million researchers have used the AI breakthrough that helps scientists better understand diseases. Here's how AlphaFold came to be. → Read More
CRISPR pioneer Feng Zhang's secretive gene-editing startup has hired ex-Alnylam leaders as CEO and chair
Akin Akinc, Alnylam's former cancer head, is CEO of Aera, which is trying to solve one of the biggest problems in the gene-editing field. → Read More
A tiny biotech just suffered a safety scare in a gene-editing trial, raising 3 big questions for the entire CRISPR field
Graphite Bio paused its study on using gene editing to treat sickle cell disease after the first treated patient had a serious side effect. → Read More
Why a top Roche scientist is leaving after 25 years to join a rising biotech startup using fungi to make new drugs
Martin Stahl will start at LifeMine next month to lead its science unit after more than two decades as a drug hunter at the Swiss pharma giant Roche. → Read More
Kids with 'bubble boy' disease are dying — even though drug companies have found a cure
Jakob, who was born with a rare illness, is 2 years old. But what's keeping him isolated from the world isn't his disease-- it's the marketplace. → Read More
Cell therapy has revolutionized cancer treatment. Now the California biotech Sangamo is trying to see if it can also upend autoimmune diseases.
Sangamo Therapeutics has given its first dose of an experimental T-cell therapy in an effort to treat autoimmune diseases, Insider has learned. → Read More
Moderna says its coronavirus shot works in young kids, and it will ask regulators to OK its use
Moderna announced that it would seek approval from the US Food and Drug Administration, the European Medicines Agency, and other global regulators. → Read More
$3.3 billion healthcare data startup Komodo Health is gearing up for an IPO in a move that could test the choppy health-tech market
Komodo Health has hired banks to go public this year. Its IPO would test the waters of a market that's been highly skeptical of health-tech stocks. → Read More
How base editing went from a research project to a gene-editing technology that could change the future of medicine and reshape a multibillion-dollar market
Less than six years after being invented, base editing is expected to start human testing this year. → Read More
After falling behind gene-editing rivals, Editas just got a much-needed win in the courtroom. Here's how it could shake up the CRISPR landscape.
Over 100 patent claims related to gene-editing tech "just got wiped off the face of the earth," a legal analyst said. → Read More
Exclusive: Verily-backed startup Galvani just implanted a US patient with an experimental bioelectronic device to treat arthritis
Galvani Bioelectronics' electronic implant was in development for five years. "The potential here is huge," experts say. → Read More
The first human study has launched to treat HIV patients with CRISPR. The CEO of the gene-editing startup says it could be a one-time cure.
The first participants should be enrolled soon, and initial results are expected before year's end, Excision CEO Daniel Dornbusch told Insider. → Read More
Missed M&A hopes and next-generation gene therapy deals: Here are the 3 winners and 3 losers from the drug industry's biggest event
More than 625 healthcare companies laid out their plans for 2022 and beyond at the J.P. Morgan conference this week. Here are the winners and losers. → Read More
Meet the 28 startups the biggest investor in biotech is betting on this year
Arch Venture backed 28 startups in 2021, participating in financings ranging from a $3.8 million seed round to a $500 million Series B round. → Read More
These gene-editing startups are aiming to solve one of CRISPR's biggest problems. Here's how they could upend biotech in 2022.
"The era of CRISPR is just beginning," said Benjamin Oakes, the CEO of the gene-editing startup Scribe Therapeutics. → Read More
The FDA just authorized the first pill to treat COVID-19, replenishing the tool kit of treatments against Omicron
Pfizer's pill was found to be highly effective at preventing hospitalizations and deaths among people who recently got COVID-19. → Read More
Why 2022 will be CRISPR's most important year, according to more than 20 gene-editing experts
* 2022 is set to be an inflection point for gene editing as more biotechs start human testing. * The technology holds the potential to cure certain genetic diseases. * Insider talked with experts across the drug industry to learn how gene editing could evolve in 2022. 2022 will be a critical year of execution for the gene-editing technology known as CRISPR. Several biotechs are advancing into… → Read More
Here's the data we have so far on the Omicron variant versus our vaccines — what scientists have found, and what remains unanswered
The first lab findings are flying in from scientists around the world. Here's what we know so far on how COVID-19 vaccines are impacted by Omicron. → Read More
Here are the 18 investors set to shape biotech in 2022
Insider analyzed more than 90 IPOs to find the top venture capitalists that ran biotech in 2021. These 18 firms are shaping the future of biotech. → Read More
The First Study Assessing Pfizer's Effectiveness Against Omicron Just Came Out
The Omicron variant substantially reduced antibody levels generated by the Pfizer-BioNTech COVID-19 vaccine, according to preliminary results from a South African study that's still awaiting peer review. → Read More